The trademark application ÆTERNA ZENTARIS was filed by AEterna Zentaris GmbH, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). The application was published for oppositions on May 3, 2020, and it was registered by office on August 10, 2020 without any oppositions.
The application was filed in English (German was selected as the second language).
Change of name and professional address of the trademark registration was recorded on May 13, 2020.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations used for the treatment of cancer
Pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer
Pharmaceutical preparations used for the treatment of urological diseases
Pharmaceutical preparations used for the treatment of hormonal disorders
Peptides containing pharmaceutical preparations used for hormonal and tumors treatments
Pharmaceutical preparations used for the treatment of endocrine diseases
Pharmaceutical preparations used for the treatment of carcinoid tumors
Pharmaceutical preparations used for the treatment of haematological diseases
Pharmaceutical preparations used for the treatment of age-related diseases
Pharmaceutical preparations used for the treatment of ophthalmological disorders
Pharmaceutical preparations used for the treatment of reproductive system disorders
Pharmaceutical preparations used for the treatment of endometriosis
Pharmaceutical preparations used for the treatment of uterine myoma
Pharmaceutical preparations used for the treatment of non-malignant tumors
Pharmaceutical preparations used for the treatment of benign prostatic hyperplasia (BPH)
Pharmaceutical preparations used for the treatment of tropical diseases
Pharmaceutical preparations used for the treatment of infectious disease
Pharmaceutical preparations used for the treatment of leishmaniasis
Pharmaceutical preparations used for the treatment of obesity
Pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes
Pharmaceutical preparations containing cytotoxic products (conjugated or not)
Pharmaceutical preparations used as a tubulin inhibitor
Pharmaceutical preparations based on LHRH antagonists platform
Pharmaceutical preparations based on bombesin antagonist platform
Pharmaceutical preparations based on inhibitors of the Akt pathway
Pharmaceutical preparations based on angiogenesis inhibitors platform
Pharmaceutical preparations used to induce apoptosis
Pharmaceutical preparations used to stimulate growth hormone secretagogue (GHS)
Tumor vaccines
Pharmaceutical preparations for the treatment of cardiovascular diseases
Preparations for the treatment of respiratory diseases
Pharmaceutical preparations for the treatment of gastrointestinal diseases
Diagnostic agents
Pharmaceutical products for the treatment of neurological disorders
Pharmaceutical preparations for the treatment of nasopharyngeal disorders
Antibiotics
Antibacterial and fungicidal preparations
Pharmaceutical preparations for the treatment of mental health
Pharmaceutical preparations for the treatment of autoimmune diseases
Pharmaceutical preparations for the treatment of rheumatoid diseases
Pharmaceutical preparations for contraceptives and women's health
Analgesic pharmaceutical products
Sedativa and pharmaceutical preparations for the treatment of psychiatric disorders
Pharmaceutical preparations for the treatment of pain
Pharmaceutical preparations for palliative treatments
Pharmaceutical preparations for the treatment of addictions
Pharmaceutical formulations for the treatment of paediatric indications.